Studies have suggested that ACE2 has a renoprotective role in experimental renal diseases, including DN, particularly in combination with decreased ACE activity (Ye et al., 2004), because it enhances the degradation of Ang II (Batlle et al., 2012). Here, ACE2 is linked to kidney disorder.